1
|
Stinchcombe TE, Bogart J, Veeramachaneni
NK, Kratzke R and Govindan R: Annual review of advances in
non-small cell lung cancer research: A report for the year 2010. J
Thorac Oncol. 6:1443–1450. 2011. View Article : Google Scholar : PubMed/NCBI
|
2
|
Horner MJ, Ries LAG, Krapcho M, Neyman N,
Aminou R, Howlader N, Altekruse SF, Feuer EJ, Huang L, Mariotto A,
et al: National Cancer Institute SEER cancer statistics review.
1975-2006, http://seer.cancer.gov/csr/1975_2006November.
2009
|
3
|
Ding L, Getz G, Wheeler DA, Mardis ER,
McLellan MD, Cibulskis K, Sougnez C, Greulich H, Muzny DM, Morgan
MB, et al: Somatic mutations affect key pathways in lung
adenocarcinoma. Nature. 455:1069–1075. 2008. View Article : Google Scholar : PubMed/NCBI
|
4
|
Cancer Genome Atlas Research Network:
Comprehensive genomic characterization of squamous cell lung
cancers. Nature. 489:519–525. 2012. View Article : Google Scholar : PubMed/NCBI
|
5
|
Francia G, Cruz-Munoz W, Man S, Xu P and
Kerbel RS: Mouse models of advanced spontaneous metastasis for
experimental therapeutics. Nat Rev Cancer. 11:135–141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Paget S: The distribution of secondary
growths in cancer of the breast. Lancet. 133:571–573. 1889.
View Article : Google Scholar
|
7
|
Wilmanns C, Fan D, O'Brian CA, Bucana CD
and Fidler IJ: Orthotopic and ectopic organ environments
differentially influence the sensitivity of murine colon carcinoma
cells to doxorubicin and 5-fluorouracil. Int J Cancer. 52:98–104.
1992. View Article : Google Scholar : PubMed/NCBI
|
8
|
Fidler IJ: Models for spontaneous
metastasis. Cancer Res. 66:97872006. View Article : Google Scholar : PubMed/NCBI
|
9
|
Peterson JK and Houghton PJ: Integrating
pharmacology and in vivo cancer models in preclinical and clinical
drug development. Eur J Cancer. 40:837–844. 2004. View Article : Google Scholar : PubMed/NCBI
|
10
|
Miyoshi T, Kondo K, Ishikura H, Kinoshita
H, Matsumori Y and Monden Y: SCID mouse lymphogenous metastatic
model of human lung cancer constructed using orthotopic inoculation
of cancer cells. Anticancer Res. 20:161–163. 2000.PubMed/NCBI
|
11
|
Ishikura H, Kondo K, Miyoshi T, Kinoshita
H, Hirose T and Monden Y: Artificial lymphogenous metastatic model
using orthotopic implantation of human lung cancer. Ann Thorac
Surg. 69:1691–1695. 2000. View Article : Google Scholar : PubMed/NCBI
|
12
|
Ishikura H, Kondo K, Miyoshi T, Kinoshita
H, Takahashi Y, Fujino H and Monden Y: Suppression of mediastinal
metastasis by uracil-tegafur or cis-diamminedichloroplatinum(II)
using a lymphogenous metastatic model in a human lung cancer cell
line. Clin Cancer Res. 7:4202–4208. 2001.PubMed/NCBI
|
13
|
Fujino H, Kondo K, Miyoshi T, Ishikura H,
Takahashi Y, Sawada N, Hirose Y, Takizawa H, Nagao T, Sakiyama S,
et al: Establishment of patient-like SCID mouse model by
orthotopically implanting primary cultured cells from
surgically-resected lung cancer tissues. Oncol Rep. 10:1709–1715.
2003.PubMed/NCBI
|
14
|
Fujino H, Kondo K, Ishikura H, Maki H,
Kinoshita H, Miyoshi T, Takahashi Y, Sawada N, Takizawa H, Nagao T,
et al: Matrix metalloproteinase inhibitor MMI-166 inhibits
lymphogenous metastasis in an orthotopically implanted model of
lung cancer. Mol Cancer Ther. 4:1409–1416. 2005. View Article : Google Scholar : PubMed/NCBI
|
15
|
Takizawa H, Kondo K, Toba H, Kenzaki K,
Sakiyama S and Tangoku A: Fluorescence diagnosis of lymph node
metastasis of lung cancer in a mouse model. Oncol Rep. 22:17–21.
2009.PubMed/NCBI
|
16
|
Sauter AW, Spira D, Schulze M, Pfannenberg
C, Hetzel J, Reimold M, Klotz E, Claussen CD and Horger MS:
Correlation between [18F]FDG PET/CT and volume perfusion
CT in primary tumours and mediastinal lymph nodes of non-small-cell
lung cancer. Eur J Nucl Med Mol Imaging. 40:677–684. 2013.
View Article : Google Scholar : PubMed/NCBI
|
17
|
Walker CM, Chung JH, Abbott GF, Little BP,
El-Sherief AH, Shepard JA and Lanuti M: Mediastinal lymph node
staging: From noninvasive to surgical. AJR Am J Roentgenol.
199:W54–W64. 2012. View Article : Google Scholar : PubMed/NCBI
|
18
|
Silvestri GA, Gould MK, Margolis ML,
Tanoue LT, McCrory D, Toloza E and Detterbeck F: American College
of Chest Physicians: Noninvasive staging of non-small cell lung
cancer: ACCP evidenced-based clinical practice guidelines (2nd
edition). Chest. 132((3 Suppl)): 178S–201S. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Mokhtar M, Kondo K, Takizawa H, Ohtani T,
Otsuka H, Kubo H, Kajiura K, Nakagawa Y, Kawakami Y, Yoshida M, et
al: Non-invasive monitoring of anticancer effects of cisplatin on
lung cancer in an orthotopic SCID mouse model using
[18F] FDG PET-CT. Oncol Rep. 31:2007–2014. 2014.
View Article : Google Scholar : PubMed/NCBI
|
20
|
Wang W, Li Q, Yamada T, Matsumoto K,
Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S and
Yano S: Crosstalk to stromal fibroblasts induces resistance of lung
cancer to epidermal growth factor receptor tyrosine kinase
inhibitors. Clin Cancer Res. 15:6630–6638. 2009. View Article : Google Scholar : PubMed/NCBI
|
21
|
Ishikawa D, Takeuchi S, Nakagawa T, Sano
T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, et al:
mTOR inhibitors control the growth of EGFR mutant lung cancer even
after acquiring resistance by HGF. PLoS One. 8:e621042013.
View Article : Google Scholar : PubMed/NCBI
|
22
|
Nanjo S, Ebi H, Arai S, Takeuchi S, Yamada
T, Mochizuki S, Okada Y, Nakada M, Murakami T and Yano S: High
efficacy of third generation EGFR inhibitor AZD9291 in a
leptomeningeal carcinomatosis model with EGFR-mutant lung cancer
cells. Oncotarget. 7:3847–3856. 2016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Johnson DH, Schiller JH and Bunn PA Jr:
Recent clinical advances in lung cancer management. J Clin Oncol.
32:973–982. 2014. View Article : Google Scholar : PubMed/NCBI
|
24
|
Noonan KL, Ho C, Laskin J and Murray N:
The influence of the evolution of first-line chemotherapy on
steadily improving survival in advanced non-small-cell lung cancer
clinical trials. J Thorac Oncol. 10:1523–1531. 2015. View Article : Google Scholar : PubMed/NCBI
|